A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-2595 ◽

2021 ◽

pp. clincanres.2595.2021

Author(s):

Qing Zhou ◽

Lin Wu ◽

Pei Hu ◽

Tongtong An ◽

Jianying Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer

Molecular Medicine Reports ◽

10.3892/mmr.2020.11686 ◽

2020 ◽

Vol 23 (1) ◽

pp. 1-1

Author(s):

Yingjie Lu ◽

Dongliang Bian ◽

Xuelin Zhang ◽

Huibiao Zhang ◽

Zhenghong Zhu

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Targeted Oncology ◽

10.1007/s11523-017-0479-4 ◽

2017 ◽

Vol 12 (2) ◽

pp. 153-161 ◽

Author(s):

Salvatore Corallo ◽

Ettore D’Argento ◽

Antonia Strippoli ◽

Michele Basso ◽

Santa Monterisi ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Treatment Options ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations

Drugs of Today ◽

10.1358/dot.2016.52.10.2541343 ◽

2016 ◽

Vol 52 (10) ◽

pp. 561 ◽

Author(s):

C.E. McCoach ◽

A. Jimeno

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Third Generation ◽

Small Cell Lung ◽

Download Full-text

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3321505 ◽

2019 ◽

Author(s):

Yi-Chen Zhang ◽

Zhi-Hong Chen ◽

Xu-Chao Zhang ◽

Chong-Rui Xu ◽

Hong-Hong Yan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Clinical Strategy

Download Full-text

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3341474 ◽

2019 ◽

Author(s):

Yi-Chen Zhang ◽

Zhi-Hong Chen ◽

Xu-Chao Zhang ◽

Chong-Rui Xu ◽

Hong-Hong Yan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Third Generation ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Clinical Strategy

Download Full-text

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

Calpain4 Regulates The Response Of Non-Small Cell Lung Cancer Cell Lines To EGFR Tyrosine Kinase Inhibitor Erlotinib

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6288 ◽

2012 ◽

Author(s):

Sucheta Kulkarni ◽

Leya Saju ◽

Carol F. Farver

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lung Cancer Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAÏVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS

Respirology ◽

10.1111/resp.13207_77 ◽

2017 ◽

Vol 22 ◽

pp. 114-114 ◽

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Clinical Analysis ◽

Egfr Mutations ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Abstract 3802: Effect of CS-7017, a selective PPARδ agonist, on the TGFβ/Smad-mediated enhanced cell motility of EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

10.1158/1538-7445.am2012-3802 ◽

2012 ◽

Author(s):

Masakuni Serizawa ◽

Masaru Watanabe ◽

Junko Suzuki ◽

Akane Naruoka ◽

Haruyasu Murakami ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Motility ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cells ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-019-00887-0 ◽

2019 ◽

Vol 38 (3) ◽

pp. 874-884

Author(s):

Weiwei Tan ◽

Nagdeep Giri ◽

Susan Quinn ◽

Keith Wilner ◽

Kourosh Parivar

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Potential Effect ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text